{"id":10961,"date":"2003-04-01T09:43:41","date_gmt":"2003-04-01T09:43:41","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10961"},"modified":"2014-05-28T16:00:23","modified_gmt":"2014-05-28T16:00:23","slug":"indian-generic-drug-maker-ranbaxy-laboratories-to-launch-own-brand-abacavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10961","title":{"rendered":"Indian generic drug maker Ranbaxy Laboratories to launch own-brand abacavir"},"content":{"rendered":"<p><strong>Ranbaxy Laboratories, India\u2019s largest drug maker in terms of sales, has launched a new antiretroviral drug, which is a generic formulation of a patented medication made by GlaxoSmithKline, Dow Jones International News reports.<\/strong><\/p>\n<p>The Ranbaxy drug, which is equivalent to GSK\u2019s abacavir (Ziagen), will be sold under the brand name Virol in 300 milligram tablets. According to a Ranbaxy spokesperson, the drug, which is taken twice a day, will cost about $136 a month, with an Indian market size of approximately $6.3 million. \u201cThe company will be able to carve out a sizable share of the market as most other drugs in currency are older molecules,\u201d Sri Hari, a pharmaceutical analyst with Mumbai-based brokerage Khandwala Securities, said. The antiretroviral drug market in India is about $31.4 million a year, with Indian drug makers Aurobindo Pharma and Cipla playing large roles (Dow Jones International News).<\/p>\n<p>Source: Kaiser Daily Report<\/p>\n<p><a href=\"http:\/\/www.kaisernetwork.org\/daily_reports\/rep_index.cfm?DR_ID=15876\">http:\/\/www.kaisernetwork.org\/daily_reports\/rep_index.cfm?DR_ID=15876<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ranbaxy Laboratories, India\u2019s largest drug maker in terms of sales, has launched a new antiretroviral drug, which is a generic formulation of a patented medication made by GlaxoSmithKline, Dow Jones International News reports. The Ranbaxy drug, which is equivalent to &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-10961","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10961"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10961\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}